Most data reported similar serum visfatin levels in NAFLD [108], simple steatosis (SS) [109], or NASH patients [109,110] compared to control subjects, as well as in NASH compared to SS patients [109,111]. This evidence concerns the gene NAMPT and metabolic dysfunction-associated steatotic liver disease.